{'fraction_non_alphanumeric': 0.017953321364452424, 'fraction_numerical': 0.0017953321364452424, 'mean_word_length': 5.488372093023256, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
BTLA, a new inhibitory B7 family receptor with a TNFR family ligand.

B and T lymphocyte attenuator (BTLA), identified as an immune inhibitory receptor recently, plays widespread roles on T and B cells. Emerging evidence has generated plentiful information on the mechanisms which BTLA mediates negative regulation in immune responses and involves in a variety of physiological and pathological processes. The exploration of the biological mechanisms and regulation of BTLA will open possibilities on novel therapeutic strategies in immune-related diseases.